ESMO Breast 2026: Long-term evidence confirms reproducibility and value of local EndoPredict testing

 

New data presented at ESMO Brustkrebs 2026 provide robust long-term evidence supporting the reproducibility of EndoPredict in routine clinical practice across decentralized laboratory settings.

The results are based on an 8-year national external quality control program in France (2017–2025), in which EndoPredict was repeatedly evaluated across multiple local routine laboratories under real-world conditions. Using shared reference samples tested over time, the program enabled one of the most comprehensive long-term assessments of inter-laboratory consistency in breast cancer genomic testing.

 

Across repeated measurements and multiple sites, EndoPredict demonstrated:

• 100% concordance in risk classification (low vs high risk) in repeated sample analyses
• High analytical reproducibility of the EPclin score under routine conditions
• Stable molecular score performance over an extended time period
• Consistent model-derived 10-year recurrence risk estimates
• Long-term technical robustness across laboratories and analytical platforms
• Stable gene expression measurements across repeated testing

Importantly, these results reflect performance in routine decentralized laboratory practice, where testing is performed locally as part of standard clinical workflows and continuously monitored through external quality control over time.

 

Relevance of local testing in clinical practice

 

Decentralized, locally performed genomic testing offers several practical advantages for healthcare systems and patient care:

• Proximity to the patient, enabling timely access to results and supporting faster clinical decision-making
• Integration into local laboratory infrastructure, allowing testing to be embedded directly within routine care pathways
• Locally controlled quality assurance, supported by structured external quality control programs across sites
• Strengthening of regional laboratory expertise and infrastructure, contributing to the maintenance of highly specialized diagnostic capabilities within healthcare systems
• Reduced logistical burden and improved efficiency, by avoiding sample transport to central facilities

In addition, local testing models may contribute to more sustainable healthcare delivery, by reducing the need for long-distance sample transport and associated logistics, thereby potentially lowering the overall environmental footprint of diagnostic workflows.

Conclusion

 

These data support the robustness and consistency of EndoPredict in real-world diagnostic use and illustrate how high-quality genomic testing can be reliably delivered within decentralized laboratory networks and embedded in routine clinical practice.

Access the full poster here: POSTER

 

Reference:

Lehmann-Che J. et al. High robustness and reproducibility of the genomic signature EndoPredict through quality control programs in France since 2017. ESMO Breast 2026 150eP